Previous Close | 1,254.65 |
Open | 1,226.25 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 1,226.25 - 1,264.65 |
52 Week Range | 665.75 - 1,292.10 |
Volume | |
Avg. Volume | 1,612,318 |
Market Cap | 736.729B |
Beta (5Y Monthly) | 0.51 |
PE Ratio (TTM) | 23.25 |
EPS (TTM) | 54.14 |
Earnings Date | Aug 10, 2024 - Aug 14, 2024 |
Forward Dividend & Yield | 4.50 (0.36%) |
Ex-Dividend Date | Feb 20, 2024 |
1y Target Est | 953.00 |
Aurobindo Pharma (NS:ARBN) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year growth. Sales increased by 17%, while EBITDA surged by an impressive 68%, surpassing both Goldman Sachs (NYSE:GS)' projections and those of the broader market. The EBITDA margin also exceeded forecasts, reaching 22.3%, which is 101 basis points higher than Goldman Sachs' estimate.